**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Decision Cover Letter

## Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral

MHRA-101701-PIP01-24

# Scope of the Application

## Active Substance(s)

BBP-418; ribitol

## Condition(s)

Treatment of limb-girdle muscular dystrophy

## Pharmaceutical Form(s)

Oral powder Age appropriate oral dosage form

## Route(s) of Administration

ORAL USE

## Name / Corporate name of the PIP applicant

ML Bio Solutions Inc.

## Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, ML Bio Solutions Inc. submitted to the licensing authority on 13/02/2025 22:39 GMT an application for a

The procedure started on 05/03/2025 17:50 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Final Decision Letter

MHRA-101701-PIP01-24

Of 09/06/2025 09:34 BST

On the adopted decision for BBP-418; ribitol (MHRA-101701-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a for BBP-418; ribitol, Oral powder Age appropriate oral dosage form , ORAL USE .

This decision is addressed to ML Bio Solutions Inc., 1800 Owens Street Suite C1200, San Francisco, UNITED STATES OF AMERICA, 94158

## ANNEX I

### 1. Waiver

### 1.1 Condition:

| |
|---|
| Not applicable |

### 2. Paediatric Investigation Plan:

### 2.1 Condition(s):

| |
|---|
| Treatment of limb-girdle muscular dystrophy |

### 2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients from birth to less than 18 years of age with a genetically confirmed diagnosis of Limb-Girdle muscular dystrophy (LGMD) type 2i/ LGMD R9-fukutin related or subtypes LGMD2M and LGMD2U.

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

### 2.4 Pharmaceutical Form(s):

Oral powder Age appropriate oral dosage form

### 2.5 Studies:

| Study Type | Number of Studies | Study Description |
|---|---|---|
| **Quality Measures** | 1 | Study 1 Development of an age-appropriate oral dosage form (powder for oral use) suitable for children younger than 12 years of age including age appropriate excipients and age-appropriate flavourings. |
| **Non-Clinical Studies** | 1 | Study 2 Definitive juvenile toxicity study in rats. |
| **Clinical Studies** | 5 | Study 3 (MLB-01-003) Open label, single arm study to assess the safety, tolerability and pharmacokinetics of ascending doses of ribitol in paediatric patients from 12 years to less than 18 years of age (and adults) with limb girdle muscular dystrophy (LGMD) 2I. Study 4 (MLB-01-005) Double blind, placebo controlled study to assess pharmacokinetics, safety and efficacy of ribitol compared to placebo in paediatric patients from 12 years to less than 18 years of age (and adults) with limb girdle muscular dystrophy (LGMD) 2I. Study 5 Open label, single arm trial to evaluate the safety, pharmacokinetics and pharmacodynamics and selected clinical activity of ribitol in paediatric patients from birth to less than 12 years of age with genetically confirmed limb girdle muscular dystrophy 2I/R9. Study 6 Open label, single arm study to assess the |

| | | |
|---|---|---|
| | | safety, tolerability, pharmacokinetics and clinical activity of ribitol in paediatric patients from birth to less than 18 years of age (and adults) with limb girdle muscular dystrophy type 2M and 2U. Study 7 (MLB-01-001) Observational study aimed at collecting data on clinical outcome assessments in paediatric patients from 10 years to less than 18 years of age (and adults) with Limb Girdle muscular dystrophy type 2I/ R9 (LGMD2I/R9). |
| **Extrapolation, Modeling & Simulation Studies** | 2 | Study 8 Modelling and simulation study to further determine the dose of ribitol to be used in paediatric patients from birth to less than 18 years of age with limb girdle muscular dystrophy type 2. Study 9 Exposure-Response (E-R) model to describe the relationship between ribitol and ADG glycosylation in paediatric patients from birth to less than 18 years of age with limb girdle muscular dystrophy type 2. |
| **Other Studies** | 0 | Not applicable. |
| **Other Measures** | 0 | Not applicable. |

**3. Follow-up, completion and deferral of a PIP:**

| | |
|---|---|
| **Concerns on potential long term safety and efficacy issues in relation to paediatric use:** | No |
| **Date of completion of the paediatric investigation plan:** | 31/12/2031 |
| **Deferral of one or more studies contained in the paediatric investigation plan:** | Yes |